vs
AGENUS INC（AGEN）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
过去两年AGENUS INC的营收复合增速更高（10.5% vs -100.0%）
Agenus Inc.是一家总部位于美国马萨诸塞州列克星敦的生物技术公司，核心业务聚焦免疫治疗领域，尤其专注于利用人体免疫系统控制或治愈癌症的肿瘤免疫治疗。公司目前正在研发检查点调节剂、个性化抗癌疫苗，以及可适配多种疫苗的免疫佐剂，其中检查点调节剂作为当前进展迅速的方向，早期产品已为患者带来突破性临床获益。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
AGEN vs RVMD — 直观对比
营收规模更大
AGEN
是对方的Infinity倍
$0
两年增速更快
AGEN
近两年复合增速
-100.0%
损益表 — Q4 2025 vs Q4 2024
| 指标 | | |
|---|---|---|
| 营收 | $34.2M | $0 |
| 净利润 | $-10.6M | $-194.6M |
| 毛利率 | — | — |
| 营业利润率 | 42.1% | — |
| 净利率 | -31.0% | — |
| 营收同比 | 27.5% | — |
| 净利润同比 | 77.3% | -20.4% |
| 每股收益（稀释后） | $0.09 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGENRVMD
| Q4 25 | $34.2M | — | ||
| Q3 25 | $30.2M | — | ||
| Q2 25 | $25.7M | — | ||
| Q1 25 | $24.1M | — | ||
| Q4 24 | $26.8M | $0 | ||
| Q3 24 | $25.1M | $0 | ||
| Q2 24 | $23.5M | $0 | ||
| Q1 24 | $28.0M | $0 |
净利润AGENRVMD
| Q4 25 | $-10.6M | — | ||
| Q3 25 | $63.9M | — | ||
| Q2 25 | $-30.0M | — | ||
| Q1 25 | $-26.4M | — | ||
| Q4 24 | $-46.8M | $-194.6M | ||
| Q3 24 | $-67.2M | $-156.3M | ||
| Q2 24 | $-54.8M | $-133.2M | ||
| Q1 24 | $-63.5M | $-116.0M |
毛利率AGENRVMD
| Q4 25 | — | — | ||
| Q3 25 | 97.9% | — | ||
| Q2 25 | 99.1% | — | ||
| Q1 25 | 99.4% | — | ||
| Q4 24 | 99.6% | — | ||
| Q3 24 | 99.4% | — | ||
| Q2 24 | 99.5% | — | ||
| Q1 24 | 99.6% | — |
营业利润率AGENRVMD
| Q4 25 | 42.1% | — | ||
| Q3 25 | -15.0% | — | ||
| Q2 25 | -65.0% | — | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -96.5% | — | ||
| Q3 24 | -125.5% | — | ||
| Q2 24 | -128.4% | — | ||
| Q1 24 | -117.4% | — |
净利率AGENRVMD
| Q4 25 | -31.0% | — | ||
| Q3 25 | 211.4% | — | ||
| Q2 25 | -116.8% | — | ||
| Q1 25 | -109.6% | — | ||
| Q4 24 | -174.4% | — | ||
| Q3 24 | -267.7% | — | ||
| Q2 24 | -233.1% | — | ||
| Q1 24 | -226.6% | — |
每股收益（稀释后）AGENRVMD
| Q4 25 | $0.09 | — | ||
| Q3 25 | $1.94 | — | ||
| Q2 25 | $-1.00 | — | ||
| Q1 25 | $-1.03 | — | ||
| Q4 24 | $-1.95 | $-1.13 | ||
| Q3 24 | $-3.08 | $-0.94 | ||
| Q2 24 | $-2.52 | $-0.81 | ||
| Q1 24 | $-3.04 | $-0.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $2.3B |
| 总债务越低越好 | $44.7M | — |
| 股东权益账面价值 | $-271.1M | $2.3B |
| 总资产 | $226.8M | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AGENRVMD
| Q4 25 | $3.0M | — | ||
| Q3 25 | $3.5M | — | ||
| Q2 25 | $9.5M | — | ||
| Q1 25 | $18.5M | — | ||
| Q4 24 | $40.4M | $2.3B | ||
| Q3 24 | $44.8M | $1.5B | ||
| Q2 24 | $93.7M | $1.6B | ||
| Q1 24 | $52.9M | $1.7B |
总债务AGENRVMD
| Q4 25 | $44.7M | — | ||
| Q3 25 | $34.2M | — | ||
| Q2 25 | $33.9M | — | ||
| Q1 25 | $33.6M | — | ||
| Q4 24 | $33.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AGENRVMD
| Q4 25 | $-271.1M | — | ||
| Q3 25 | $-274.1M | — | ||
| Q2 25 | $-354.6M | — | ||
| Q1 25 | $-341.8M | — | ||
| Q4 24 | $-326.4M | $2.3B | ||
| Q3 24 | $-292.3M | $1.6B | ||
| Q2 24 | $-241.3M | $1.6B | ||
| Q1 24 | $-201.4M | $1.7B |
总资产AGENRVMD
| Q4 25 | $226.8M | — | ||
| Q3 25 | $233.9M | — | ||
| Q2 25 | $185.2M | — | ||
| Q1 25 | $200.2M | — | ||
| Q4 24 | $226.3M | $2.6B | ||
| Q3 24 | $238.5M | $1.8B | ||
| Q2 24 | $292.4M | $1.8B | ||
| Q1 24 | $256.6M | $1.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.6M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-139.5M |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-567.7M |
8季度趋势，按日历期对齐
经营现金流AGENRVMD
| Q4 25 | $-16.6M | — | ||
| Q3 25 | $-14.7M | — | ||
| Q2 25 | $-20.2M | — | ||
| Q1 25 | $-25.6M | — | ||
| Q4 24 | $-28.7M | $-138.3M | ||
| Q3 24 | $-53.3M | $-130.4M | ||
| Q2 24 | $-38.2M | $-128.2M | ||
| Q1 24 | $-38.2M | $-160.6M |
自由现金流AGENRVMD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-20.2M | — | ||
| Q1 25 | $-25.6M | — | ||
| Q4 24 | $-28.7M | $-139.5M | ||
| Q3 24 | $-53.3M | $-133.9M | ||
| Q2 24 | $-38.6M | $-130.6M | ||
| Q1 24 | $-38.2M | $-163.7M |
自由现金流率AGENRVMD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -78.7% | — | ||
| Q1 25 | -106.5% | — | ||
| Q4 24 | -107.0% | — | ||
| Q3 24 | -212.2% | — | ||
| Q2 24 | -164.4% | — | ||
| Q1 24 | -136.5% | — |
资本支出强度AGENRVMD
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 0.1% | — |
现金转化率AGENRVMD
| Q4 25 | — | — | ||
| Q3 25 | -0.23× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
